Munn R, Camfield P, Camfield C, Dooley J
Department of Paediatrics, Izaak Walton Killam Hospital for Children, Dalhousie University, Halifax, Nova Scotia, Canada.
Can J Neurol Sci. 1988 Nov;15(4):406-8.
Clobazam is a new benzodiazepine recently introduced in Canada on an experimental basis. We report our experience with 27 children (average age 9.1 years) with severe intractable seizure disorders. All had mixed seizures (41% focal plus generalized, 59% mixed generalized) and 93% were mentally retarded. Eighty-five percent had multiple daily seizures and all had been on an average of 6 other anticonvulsants in the past. Forty-one percent of our patients responded to clobazam with a reduction of greater than 75% in seizure frequency and 15% had no further seizures. Tolerance to clobazam which could not be overcome by dose increases developed in 26% of patients. Forty-four percent of non-responders had exacerbations of their seizures shortly after starting clobazam, however 43% of these patients had reductions in comedications simultaneously. Side effects of clobazam in responders were minimal. We conclude that clobazam shows sufficient promise to warrant further trials in more benign seizure disorders in children.
氯巴占是一种最近在加拿大以实验为基础引入的新型苯二氮䓬类药物。我们报告了我们对27名患有严重顽固性癫痫疾病儿童（平均年龄9.1岁）的治疗经验。所有患儿均有混合性癫痫发作（41%为局灶性加全身性发作，59%为混合性全身性发作），93%智力发育迟缓。85%的患儿每天发作多次，且过去平均都使用过6种其他抗惊厥药物。我们41%的患者对氯巴占有反应，癫痫发作频率降低超过75%，15%的患者不再发作。26%的患者出现了对氯巴占的耐受性，增加剂量也无法克服。44%无反应者在开始使用氯巴占后不久癫痫发作加剧，然而这些患者中有43%同时减少了合并用药。氯巴占在有反应者中的副作用极小。我们得出结论，氯巴占显示出足够的前景，值得在儿童更良性的癫痫疾病中进行进一步试验。
